Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.14 EUR | +2.24% | +3.64% | -12.98% |
29/03 | Laboratorio Farmaceutico Erfo, revenues grow and profit remains stable | AN |
19/02 | Mib in the red at 31,600; TIM still on top | AN |
Sales 2023 * | 6.3M 6.74M 562M | Sales 2024 * | 6.5M 6.95M 580M | Capitalization | 10.26M 10.97M 915M |
---|---|---|---|---|---|
Net income 2023 * | - 0 0 | Net income 2024 * | - 0 0 | EV / Sales 2023 * | 1.37 x |
Net cash position 2023 * | 1.6M 1.71M 143M | Net cash position 2024 * | 2M 2.14M 178M | EV / Sales 2024 * | 1.27 x |
P/E ratio 2023 * |
12.7
x | P/E ratio 2024 * |
19
x | Employees | 29 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 22.6% |
1 day | +2.24% | ||
1 week | +3.64% | ||
Current month | +5.07% | ||
1 month | +4.59% | ||
3 months | -2.15% | ||
6 months | +26.11% | ||
Current year | -12.98% |
Managers | Title | Age | Since |
---|---|---|---|
Flavio Corpina
CEO | Chief Executive Officer | 45 | 01/17/01 |
Alessandro Cutè
CEO | Chief Executive Officer | 53 | 01/13/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alessandro Cutè
CEO | Chief Executive Officer | 53 | 01/13/01 |
Flavio Corpina
CEO | Chief Executive Officer | 45 | 01/17/01 |
Fabio Giuffre
BRD | Director/Board Member | 43 | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 1.14 | +2.24% | 1,000 |
25/24/25 | 1.115 | -1.33% | 4,000 |
24/24/24 | 1.13 | 0.00% | 0 |
23/24/23 | 1.13 | +2.73% | 9,000 |
22/24/22 | 1.1 | 0.00% | 0 |
Real-time Borsa Italiana, April 26, 2024 at 09:14 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.98% | 10.95M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ERFO Stock